Therapeutic compliance in the prevention of primary cardiovascular diseases with lovastatine. PRELOVAS study;Adherencia al tratamiento con lovastatina en la prevención primaria de enfermedades cardiovasculares. Estudio PRELOVAS

Medicina Clinica

Volumn 123, Issue 18, 2004, Pages 692-696

  Martín Castillo, Fidel ^a   Ayuga Martínez, Ángel ^b   Perulero Escobar, Núria ^c   Barea Escribano, Noelia ^c  

^a HOSPITAL DE MÓSTOLES   (Spain)

^b Depto Medico de Schwarz Pharma   (Spain)

^c Health Outcomes Research Europe   (Spain)

Author keywords

Cardiovascular diseases; Lipid lowering treatment; Lovastatine; Prevention; Therapeutic adherence

Indexed keywords

CHOLESTEROL; MEVINOLIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG INDICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; QUESTIONNAIRE;

EID: 11244257309     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(04)75332-4     Document Type: Article

References (16)

1. Sabate E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization, 2003. Disponible en: http://www.who.int/ chronic_conditions/adherencereport/en
2. Rand CS. Measuring adherence with therapy for chronic diseases: implications for the treatment of heterozygous familial hypercholesterolemia. Am J Cardiol 1993;72:68D-74D.
3. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997;241:317-25.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-9.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
6. Villar Alvarez F, Maiques Galán A, Brotons Cuixart C, Torcal Laguna J, Lorenzo Piqueres A, Vilaseca Canals J, et al. Prevención cardiovascular en atención primaria. Aten Primaria 2001;28(Supl 2):13-26.
7. Pearson TA, Brown WV, Oonato K, Franklin FA, Luepker RB, McBride PE, et al. Lipids Workshop IV. Circulation 1993;72:68D-74D.
8. Piñeiro F, Gil V, Pastor R, Donis M, Torres MT, Merino J. Validez de 6 métodos indirectos para valorar el cumplimiento del tratamiento farmacológico en las dislipemias. Aten Primaria 1997;19:465-8.
9. Piñeiro F, Gil V, Pastor R, Donis M, Torres MT, Merino J. Factores implicados en el incumplimiento de tratamiento farmacológico en las dislipemias. Aten Primaria 1998;21:425-30.
10. Leupker RV. Patient adherence «a risk factor for cardiovascular disease». Heart Dis Stroke 1993; 2:418-21.
11. Rudd P. Compliance with antihypertensive therapy: a shifting paradigm. Cardiol Rev 1994;2:230-40.
12. Gil VF, Belda J, Muñoz C, Martinez JL, Soriano JE, Merino J. Validez de cuatro métodos indirectos que valoran el cumplimiento terapéutico en la hipertensión arterial. Rev Clin Esp 1993;193:363-7.
13. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67-74.
14. Val Jiménez A, Amorós Ballestero G, Martinez Visa P, Fernandez Ferre ML, León Sanromá M. Estudio descriptivo del cumplimiento del tratamiento farmacológico antihipertensivo y validación del test de Morinsky y Green. Aten Primaria 1992;10:767-70.
15. Garcia Navarro MD, Orozco D, Gil V, Carratalá C, Terol C, Merino J. Relación entre cumplimento farmacológico y grado de control en pacientes con hipertensión, diabetes o dislipemia. Med Clin (Barc) 2001;116:141-6.
16. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980;303:1038-41.